Company Overview
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Why Investors Should Care
Revenue has grown at a 31.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $606.42M (+66.7% YoY); net profit $-1.28B.
- Trailing 12 Months Year-on-year growth — revenue +296.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 31.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 31.16% |
| 1 Year: | 296.10% |
Stock Price Performance
| 1 Year: | +1.64% |
| 6 Months: | -12.74% |
| 3 Months: | +32.62% |
| 1 Month: | -4.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)55.25 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 31.2% over 5 years.
CONS
- Trading 40.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INSM Insmed Incorporated R3KPHARMA | 124.89 | -30.31 | $27.27B | 0.00% | -69.43% | -87.22% | 31.16% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.84M | 21.90M | 29.97M | 38.88M | 45.71M | 36.86M | 42.49M | 43.64M | 40.21M | 45.37M | 46.76M | 53.11M | 65.22M | 67.73M | 65.21M | 77.23M | 79.07M | 75.50M | 90.34M | 93.42M | 92.82M | 107.42M | 142.34M | 305.96M | 425.49M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 7.41M | 17.75M | 25.05M | 32.45M | 37.00M | 28.42M | 32.55M | 33.02M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -26.71M | -27.95M | -30.25M | -32.59M | -33.07M | -36.13M | -37.15M | -67.05M | -35.97M | -43.52M | -44.08M | -65.35M | -62.75M | -72.88M | -83.98M | -87.72M | -69.51M | -62.17M | -56.49M | -47.08M | -60.36M | -54.11M | -56.22M | -83.83M | -88.57M | -103.62M | -89.83M | -88.32M | -127.70M | -148.16M | -235.53M | -147.67M | -145.50M | -288.90M | -213.43M | -248.14M | -312.88M | -366.00M | -153.32M | -1.55M |
| Net Income | -27.37M | -28.61M | -30.96M | -31.25M | -33.53M | -36.58M | -37.76M | -68.40M | -37.41M | -44.67M | -45.18M | -65.38M | -68.52M | -76.44M | -87.74M | -91.57M | -74.15M | -66.51M | -60.68M | -52.99M | -66.36M | -61.85M | -63.66M | -91.64M | -117.32M | -112.71M | -94.62M | -95.64M | -131.15M | -159.76M | -244.81M | -158.93M | -157.09M | -300.61M | -220.52M | -256.58M | -321.69M | -370.02M | -163.56M | -13.24M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.64 | -0.63 | -0.89 | -1.07 | -0.96 | -0.80 | -0.80 | -1.09 | -1.17 | -1.78 | -1.11 | -1.06 | -1.94 | -1.27 | -1.42 | -1.70 | -1.75 | -0.76 | -0.06 |
| R&D Expense | 17.16M | 18.25M | 19.22M | - | 20.55M | 23.87M | 23.43M | - | 22.25M | 26.87M | 26.68M | - | 30.10M | 35.72M | 39.54M | - | 31.20M | 33.54M | 34.34M | - | 36.18M | 35.75M | 41.41M | 61.39M | 64.66M | 70.35M | 84.36M | 88.53M | 99.87M | 127.86M | 196.97M | 109.15M | 121.08M | 146.75M | 150.81M | 152.58M | 177.19M | 186.41M | 209.49M | 210.03M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.37M | 6.92M | 4.42M | 0 | 11.50M | - | 0 | 0 | 0 | 9.84M | 136.47M | 164.41M | 188.46M | 245.36M | 305.21M | 363.71M | 606.42M |
| Gross Profit | - | - | - | - | - | - | - | - | 0 | 7.41M | 112.25M | - | - | - | - | - | - |
| Operating Income | -8.67M | -8.09M | -61.72M | -42.44M | -55.02M | -87.36M | -117.49M | -173.40M | -188.92M | -307.34M | -235.25M | -265.23M | -375.09M | -457.32M | -709.63M | -878.25M | -1.25B |
| Net Income | 118.35M | -6.43M | -59.66M | -41.37M | -56.07M | -79.16M | -118.18M | -176.27M | -192.65M | -324.28M | -254.34M | -294.09M | -434.65M | -481.53M | -749.57M | -913.77M | -1.28B |
| Diluted EPS | 9.30 | -0.49 | -2.95 | - | - | - | - | - | - | - | -3.01 | -3.01 | -3.88 | -3.91 | -5.34 | -5.57 | -6.42 |
| R&D Expense | 9.21M | 4.70M | 28.62M | 29.78M | 44.28M | 56.29M | 74.28M | 122.72M | 109.75M | 145.28M | 131.71M | 181.16M | 272.74M | 397.52M | 571.01M | 598.37M | 771.09M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 196.26M | 139.83M | 153.56M | 176.50M | 230.86M | 356.56M | 237.96M | 462.05M | 604.56M | 742.30M | 796.15M | 1.24B | 1.66B | 1.33B | 2.03B | 2.26B |
| Total Equity | -2.82M | 123.91M | 192.84M | 134.27M | 120.88M | 143.32M | 186.24M | 311.70M | 154.48M | 361.06M | 208.27M | 261.67M | 275.88M | 410.47M | 87.95M | -331.92M | 285.38M | 738.98M |
| Cash & Equivalents | - | - | 10.74M | 14.85M | 90.78M | 113.89M | 159.23M | 282.88M | 162.59M | 381.17M | 495.07M | 487.43M | 532.76M | 716.78M | 1.07B | 482.37M | 555.03M | 510.44M |
| Long Term Debt | - | - | - | 0 | 16.22M | 16.34M | 24.86M | 22.03M | 54.79M | 55.57M | 316.56M | 335.94M | 356.32M | 566.59M | 1.13B | 1.16B | 1.10B | 540.96M |
| Total Liabilities | - | - | 3.42M | 5.57M | 32.68M | 33.17M | 44.63M | 44.86M | 83.47M | 100.99M | 396.29M | 480.62M | 520.27M | 833.04M | 1.57B | 1.66B | 1.74B | 1.53B |
| Current Liabilities | - | - | 3.34M | 4.48M | 15.75M | 16.46M | 19.63M | 22.26M | 27.99M | 44.66M | 79.73M | 85.24M | 118.81M | 135.17M | 190.24M | 225.63M | 297.53M | 468.87M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.01M | -7.72M | -30.20M | -31.01M | - | - | -100.70M | -146.71M | -159.62M | -257.98M | -250.65M | -219.35M | -363.30M | -400.44M | -536.25M | -683.88M | -935.01M |
| Investing Cash Flow | 18.73M | 5.96M | 34.36M | 61.52M | - | - | -3.45M | -4.20M | -3.00M | -14.81M | -42.27M | -6.82M | -64.28M | -34.58M | -223.60M | -583.17M | -64.58M |
| Financing Cash Flow | 2.88M | -233.00K | -50.00K | 45.42M | - | - | 227.80M | 30.67M | 381.09M | 386.74M | 285.28M | 271.00M | 612.55M | 793.27M | 168.44M | 1.34B | 954.07M |
| Capital Expenditure | -0 | -0 | -979.00K | -290.00K | -826.00K | -5.35M | -3.45M | -4.20M | -3.00M | -13.09M | -42.27M | -6.24M | -7.29M | -9.88M | -13.29M | -21.92M | -32.56M |
| Free Cash Flow | -11.01M | -7.72M | -31.18M | -31.30M | - | - | -104.15M | -150.91M | -162.62M | -271.07M | -292.92M | -225.59M | -370.59M | -410.32M | -549.53M | -705.80M | -967.58M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | 75.4% | 82.3% | - | - | - | - | - | - |
| Operating Margin % | -83.6% | -116.9% | -1,397.3% | - | -478.4% | - | - | - | - | -3,124.9% | -172.4% | -161.3% | -199.0% | -186.4% | -232.5% | -241.5% | -205.6% |
| Net Margin % | 1,140.9% | -93.0% | -1,350.8% | - | -487.6% | - | - | - | - | -3,297.2% | -186.4% | -178.9% | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% |
| ROE % | 95.5% | -3.3% | -44.4% | -34.2% | -39.1% | -42.5% | -37.9% | -114.1% | -53.4% | -155.7% | -97.2% | -106.6% | -105.9% | -547.5% | 225.8% | -320.2% | -172.8% |
| ROCE % | - | -4.2% | -45.6% | -30.8% | -34.4% | -41.4% | -35.1% | -82.6% | -45.3% | -58.6% | -35.8% | -39.2% | -33.8% | -31.2% | -64.3% | -50.8% | -69.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 7.39% | 16.14M | $1.94B |
| 2 | Blackrock Inc. | 7.24% | 15.81M | $1.90B |
| 3 | JPMORGAN CHASE & CO | 4.78% | 10.43M | $1.25B |
| 4 | Vanguard Portfolio Management LLC | 4.77% | 10.41M | $1.25B |
| 5 | Vanguard Capital Management LLC | 4.48% | 9.79M | $1.17B |
| 6 | Baker Bros. Advisors, LP | 4.03% | 8.80M | $1.06B |
| 7 | Capital International Investors | 3.77% | 8.24M | $988.57M |
| 8 | Darwin Global Management, Ltd. | 2.94% | 6.43M | $771.74M |
| 9 | Ameriprise Financial, Inc. | 2.83% | 6.18M | $741.55M |
| 10 | Orbis Allan Gray Ltd | 2.78% | 6.08M | $729.18M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INSM
Insmed: A Strong Launch And A Much Bigger Peak Sales Opportunity (NASDAQ:INSM) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNaUNkbmhtV296cnZqeFdSX2VORl9tNmZFQ0hYUE9qRThFYUUxeU1nSjVmWmMxNkUzQ1poZHFBWnhOM1BsZWcxbV9MWjlObzFhN3pmZXBZMVBpY0FwSTUzbFNNcEdvLTkydEhWWnBvTk9HX3pMbnJSMGFhckhGNHpoWERqeW9rSHFiUjJwRU…
Insmed Stock Price Forecast. Should You Buy INSM? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTFB5UTlMNjR1Ty14TW0tN01mZHctVTk2Uy1OSFNIdEJKTndhcFVwTy1Ib0N2Ylh5aG5VSXNmZkJwNWJMQ0RnMlo0MA?oc=5" target="_blank">Insmed Stock Price Forecast. Should You Buy INSM?</a> <fon…
128 new employees receive stock awards from Insmed - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQZ2l3bWREQmx3VXBtOWxhOXNrUGdJX2sxWlV6RWRnQUotNlc2QzRDTnhzV0J3VkRYR3k4dUQ1ZnpqUkNRZlNETXdNckxCeG96LWg3SzJnZGY2MndXTndvRER1TFB0dUhZYVVHeU9ybUhGMkFzcm1wZXBZbWtqcmlyVHRYdW1KTWh3ZUVvQW…
Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today - Benzinga
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPNnVyR3hFNEVZVnJkdV84TGRrTENyVk13ajNGc19obmNoZnRWTHFsNEVpY19vRUhud25Rb19kMjhmZWNGVTdfc080VUNIaUx2ZEJoLWxpLXJVckpVMmk5LW84ZmMzdm0yZ09iM281Z255eVZQLUFySEhTcE5YbEVQMURRVEpkMGdzc1plU1…
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOSjdyQ0g3LTluNVFXNXltZ1R6WkNCQjBPSVFGSE9fSGREd1EyNU9ZLU9ZVXJuY2l4OHV1YkRCZkNiWEFkMVMzN20xUnlFQ1BRMDhkb1RaVGFnNDNrSzI0Vm94dU9qRE92ZGkwMVJZMEpNeXNUUko2d1J6VjJWMXBOcjl5MXJQSUFldTEteX…
Insmed director Sharoky sells $637,650 of Insmed stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbjNmUGoxMUZOaHc1d1g3NjB4Zi0wVUxqdTQ1ZjZnTy1qZmFFWmlFOWtyQy1BdDN3aXdmYWc2ZzR6Q3R3YUJCRENiRXVxUVYzVGRNVXNvdzctM2QtX2pvLWFZcmgyM3Y5cWR1YVNqOEdJNmxQeWg4SUZUOWNHamVHZFNMN0FHOWs4SHF3cm…
INSM — Frequently Asked Questions
What is the current share price of Insmed Incorporated (INSM)?
As of 2026-09-19 21:16 PDT, Insmed Incorporated (INSM) trades at $124.89 on NasdaqGS. Its 52-week range is $91.88 to $211.41.
What is the market capitalisation of INSM?
Insmed Incorporated (INSM) has a market capitalisation of $27.27B on NasdaqGS.
What is the P/E ratio of INSM?
INSM trades at a trailing price-to-earnings (P/E) ratio of -30.31. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 34.58.
What is the return on equity (ROE) of INSM?
INSM has a return on equity (ROE) of -87.22%. Its return on capital employed (ROCE) is -69.43%.
Is INSM a good stock to buy?
This page provides a data-driven analysis of Insmed Incorporated (INSM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.